Clavis Pharma appoints chief business officer

Nicholas Adams takes the role at Norwegian firm

Clavis Pharma, a Norwegian cancer drug development company, has appointed Nicholas Adams as chief business officer. He replaces Jan Alfheim, who has become managing director of Nordic Nanovector.

For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.

Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.

Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.

You may also like

Regulatory

Anticancer agent – elacytarabine

Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Regulatory

Leukaemia treatment gains fast track designation

Clavis Pharma’s elacytarabine currently in Phase III trial
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
Subscribe now